4-(3-吡啶)-1-哌嗪羧酸-1,1-二甲基乙酯 | 223797-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(3-吡啶)-1-哌嗪羧酸-1,1-二甲基乙酯
• 英文名称: 4-(pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: 4-tert-butoxycarbonyl-1-pyridin-3-ylpiperazine；tert-butyl 4-(pyridin-3-yl)piperazin-1-carboxylate；tert-butyl 4-(pyridin-3-yl)piperazine-1-carboxylate；1-(pyridin-3-yl)-4-tert-butoxycarbonylpiperazine；1,1-dimethylethyl 4-(pyridin-3-yl)-1-piperazine-carboxylate；1-(3-pyridyl)-4-tert-butoxycarbonylpiperazine；tert-butyl 4-pyridin-3-ylpiperazine-1-carboxylate
• CAS: 223797-47-5
• 化学式: C₁₄H₂₁N₃O₂
• 分子量: 263.34
• InChiKey: LZHMIBDVBBRGDF-UHFFFAOYSA-N

物化性质

• 沸点：
  390.2±32.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(4-BOC-Piperazino)pyridine
Synonyms: tert-Butyl 4-(pyridin-3-yl)piperazine-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(4-BOC-Piperazino)pyridine
CAS number: 223797-47-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H21N3O2
Molecular weight: 263.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(3-吡啶)-1-哌嗪羧酸-1,1-二甲基乙酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以86%的产率得到1-(3-吡啶基)哌嗪
  参考文献：
  名称：

  用3-（二甲基氨基）丁基二甲基氨基甲酸酯（DMABC）和1-（吡啶-3-基）-1,4-二氮杂analog类似物探索α4β2烟碱型乙酰胆碱受体正构结合位点的分子结构

  摘要：

  乙酰胆碱结合蛋白（AChBPs）的X射线晶体结构揭示了对经典配体结合袋的两种不同可能的扩展，已知该配体结合袋可容纳多种烟碱激动剂。其中一个口袋的大小受到限制，而另一个口袋的大小却相当大，并沿着亚基之间的界面裂口突出。为了探测功能性烟碱乙酰胆碱受体（nAChRs）中的这些假定的扩展，制备了3-（二甲基氨基）丁基二甲基氨基甲酸酯（DMABC）和1-（吡啶-3-基）-1,4-二氮杂ze的细长类似物，并在神经元处进行了药理学表征异聚nAChRs。尽管新的类似物相对于母体化合物显示出较低的结合亲和力，但所选化合物的功能表征显示它们保留了部分α4β2nAChR激动剂活性。结构-活性关系数据并未表明取代基大小的上限，如果将配体结合在较小的口袋中，这是可以预期的。数据更好地与结合模式一致，在该结合模式中，取代基沿着受体的界面裂隙突出。通过对接至α4-β2nAChR界面的同源性模型以及通过表面等离振子共振生

  DOI：

  10.1016/j.ejmech.2015.07.024
• 作为产物：
  描述：

  3-溴吡啶 、 N-Boc-哌嗪 在 三乙烯二胺 、 tris(trans-1,2-bis(4-tert-butylphenyl)ethene)nickel⁽⁰⁾ 、 锌 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以80 %的产率得到4-(3-吡啶)-1-哌嗪羧酸-1,1-二甲基乙酯
  参考文献：
  名称：

  “裸镍”催化杂芳基溴胺化

  摘要：

  在这封信中，我们报道了空气稳定的“裸镍”[Ni( 4- t Bu stb) 3 ] 是（杂）芳基溴化物和N基亲核试剂之间热 C-N 键形成的有效催化剂。该催化系统的特点是“裸镍”络合物和锌，并且没有外部光源、光催化剂、外源配体和电气装置。应用该方法后，可以容纳各种带有路易斯碱性杂原子的杂芳基，并直接用一组伯胺和仲胺胺化。

  DOI：

  10.1021/acs.orglett.4c01738

文献信息

• [EN] VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE LA VASOPRESSINE, PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：BLACKTHORN THERAPEUTICS INC

  公开号：WO2019050988A1

  公开（公告）日：2019-03-14

  Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: (I) wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.

  提供了拮抗加压素受体的化合物，特别是含有这些化合物的V1a受体产品，以及它们的使用和合成方法。这些化合物具有以下结构的结构（I），或其药学上可接受的异构体、消旋体、水合物、溶剂合物、同位素或盐：（I）其中Q1、Q2、Q3、R2a、R2b、R3和X如本文所定义。
• [EN] FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS<br/>[FR] COMPOSÉS CONDENSÉS DE PYRIDINE, DE PYRIMIDINE ET DE TRIAZINE EN TANT QU'INHIBITEURS DU CYCLE CELLULAIRE
  申请人：AMGEN INC

  公开号：WO2009085185A1

  公开（公告）日：2009-07-09

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

  提供了一种化合物、药物组合物和方法，用于治疗CDK4介导的疾病，如癌症。所述化合物是融合的吡啶、嘧啶和三嗪衍生物。
• [EN] SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR TOLL
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021087181A1

  公开（公告）日：2021-05-06

  Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  公开的是Formula (I) N-氧化物化合物或其盐，其中G、A、R1和R5在此处被定义。还公开了使用这些化合物作为Toll样受体7、8或9信号抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗炎症性和自身免疫性疾病方面是有用的。
• GLYCINE COMPOUND
  申请人：Yoshihara Kousei

  公开号：US20120184520A1

  公开（公告）日：2012-07-19

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

  本发明提供了一种化合物，该化合物可用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 本发明的解决方案是，本发明者对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，并且对于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，具有用处，从而完成了本发明。本发明还涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐以及赋形剂。
• Heteroaryl diazacycloalkanes, their preparation and use;
  申请人：Neurosearch A/S

  公开号：US20040072823A1

  公开（公告）日：2004-04-15

  The present invention discloses compounds of the formula 1 any of its enantiomers or any mixture thereof, isotopes thereof or a pharmaceutically acceptable salt thereof; wherein n is 1, 2 or 3; m is 0, 1 or 2; R represents hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, or aralkyl; and R 1 represents aminophenyl; nitrophenyl; hydroxyphenyl, alkoxyphenyl; a monocyclic 5 to 6 membered heterocyclic group which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino, nitro, —COOR 3 , —CONR 2 R 3 , —NH—CO 2 R 2 , NHCO—R 2 , —OCO—NR 2 R 3 ; wherein R 2 and R 3 independently represents hydrogen or alkyl; aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; —X-alkyl-Y-alkyl wherein X and Y independently represents O, S, NH, N-alkyl or Se; and alkyl is optionally substituted with alkoxy or thioalkoxy; —X-(alkyl) o -aryl wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; —X-(alkyl) o -Z wherein o is 0 or 1 and X represents O, S, NH, N-alkyl or Se and Z represents a 5- or 6-membered monocyclic heterocyclic group; optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; a monocyclic 5 to 6 membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; or or R 1 represents a bicyclic heterocyclic group, composed of a 5 to 6 membered monocyclic heterocyclic group fused to a benzene ring, and which may be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, alkoxy-alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino, nitro, aryl optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; and a monocyclic 5 to 6 membered heterocyclic group optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl alkenyl, alkynyl, alkoxy, cycloalkoxy, alkenoxy, alkynoxy, methylenedioxy, halogen, CF 3 , OCF 3 , CN, amino and nitro; The compounds of the invention are useful as nicotinic ACh receptor ligands.

  本发明公开了以下式化合物的任一对映异构体或其混合物，同位素或其药学上可接受的盐；其中n为1、2或3；m为0、1或2；R代表氢、烷基、环烷基、环烷基烷基或芳基；以及R1代表氨基苯基；硝基苯基；羟基苯基、烷氧基苯基；一种单环5到6成员杂环基团，该基团可以被取代一次或多次，取代基选自烷基、环烷基、环烷基烷基、烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、烷氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基、硝基、—COOR3、—CONR2R3、—NH—CO2R2、NHCO—R2、—OCO—NR2R3；其中R2和R3独立地代表氢或烷基；芳基可选择地被烷基、环烷基、环烷基烷基、烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基和硝基取代一次或多次；—X-烷基-Y-烷基，其中X和Y独立地代表O、S、NH、N-烷基或Se；烷基可选择地被烷氧基或硫代烷氧基取代；—X-(烷基)o-芳基，其中o为0或1，X代表O、S、NH、N-烷基或Se；可选择地被烷基、环烷基、环烷基烷基、烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基和硝基取代一次或多次；—X-(烷基)o-Z，其中o为0或1，X代表O、S、NH、N-烷基或Se，Z代表一个5-或6-成员单环杂环基团；可选择地被烷基、环烷基、环烷基烷基、烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基和硝基取代一次或多次；一种单环5到6成员杂环基团，可选择地被烷基、环烷基、环烷基烷基、烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基和硝基取代一次或多次；或者R1代表一个双环杂环基团，由一个5到6成员单环杂环基团与苯环融合而成，可选择地被烷基、环烷基、环烷基烷基烯基、炔基、烷氧基、烷氧基-烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基、硝基、芳基可选择地被烷基、环烷基、环烷基烷基烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基和硝基取代一次或多次；以及一种单环5到6成员杂环基团，可选择地被烷基、环烷基、环烷基烷基烯基、炔基、烷氧基、环烷氧基、烯氧基、炔氧基、亚甲二氧基、卤素、CF3、OCF3、CN、氨基和硝基取代一次或多次；本发明的化合物可用作尼古丁ACh受体配体。